Press release
Acral Lentiginous Melanoma Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Acral Lentiginous Melanoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Acral Lentiginous Melanoma Pipeline Outlook [https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Acral Lentiginous Melanoma Pipeline Report
* In May 2025, Medicenna Therapeutics Inc. announced a Phase 1/2 dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
* DelveInsight's Acral Lentiginous Melanoma Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Acral Lentiginous Melanoma treatment.
* The leading Acral Lentiginous Melanoma Companies such as Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.
* Promising Acral Lentiginous Melanoma Pipeline Therapies such as Pembrolizumab (KEYTRUDA Registered ), MDNA11, Tebentafusp, IBI363, Imatinib, Nilotinib, Sunitinib and others.
Stay ahead with the most recent pipeline outlook for Acral Lentiginous Melanoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Acral Lentiginous Melanoma Treatment Drugs [https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Acral Lentiginous Melanoma Emerging Drugs Profile
* MDNA11: Medicenna Therapeutics, Inc.
MDNA11 is a long-acting IL-2 Superkine that has been fused with human recombinant albumin, which increases its half-life and minimizes dosing requirements without sacrificing efficacy and safety. This Superkine has been designed to preferentially bind the IL-2 beta receptor (IL-2R) on immune cells and to become a powerful switch for activating and proliferating the immune cells needed to fight cancer. It is being developed specifically as a therapeutic for various solid tumors, potentially in combination with other immunotherapies. MDNA11 has the ability to preferentially stimulate cancer-fighting NK cells and naive CD8 cells instead of immuno-suppressive regulatory T cells, by 80 and 200 fold, respectively, when compared to native IL-2. It does so by specifically binding to IL-2R. and begins a cascade of events that overcomes the immune-suppressing effects of cancer and activates the cancer-killing immune cells - including cytotoxic T cells, naive T cells, and natural killer cells. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Acral Lentiginous Melanoma.
The Acral Lentiginous Melanoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Acral Lentiginous Melanoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acral Lentiginous Melanoma Treatment.
* Acral Lentiginous Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Acral Lentiginous Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acral Lentiginous Melanoma market
Explore groundbreaking therapies and clinical trials in the Acral Lentiginous Melanoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Acral Lentiginous Melanoma Drugs [https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Acral Lentiginous Melanoma Companies
Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.
Acral lentiginous melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Acral Lentiginous Melanoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Acral Lentiginous Melanoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Acral Lentiginous Melanoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Acral Lentiginous Melanoma Pipeline Report
* Coverage- Global
* Acral Lentiginous Melanoma Companies- Tizona Therapeutics Inc., Turnstone Biologics, Medicenna Therapeutics Inc., Innovent Biologics and others.
* Acral Lentiginous Melanoma Pipeline Therapies- Pembrolizumab (KEYTRUDA Registered ), MDNA11, Tebentafusp, IBI363, Imatinib, Nilotinib, Sunitinib and others.
* Acral Lentiginous Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acral Lentiginous Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Acral Lentiginous Melanoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Acral Lentiginous Melanoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Acral lentiginous melanoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Acral lentiginous melanoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* IBI-310: Innovent Biologics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* MDNA11: Medicenna Therapeutics, Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Acral lentiginous melanoma Key Companies
* Acral lentiginous melanoma Key Products
* Acral lentiginous melanoma- Unmet Needs
* Acral lentiginous melanoma- Market Drivers and Barriers
* Acral lentiginous melanoma- Future Perspectives and Conclusion
* Acral lentiginous melanoma Analyst Views
* Acral lentiginous melanoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acral-lentiginous-melanoma-pipeline-appears-robust-with-3-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acral Lentiginous Melanoma Pipeline Appears Robust With 3+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4047716 • Views: …
More Releases from ABNewswire
What are the most effective medical therapies for managing excess body mass? Reg …
Cape Coral healthcare providers report breakthrough success using FDA-approved GLP-1 medications for weight management, with Premier Wellness Florida leading comprehensive treatment programs combining pharmaceuticals with holistic wellness support.
Cape Coral, FL - Recent clinical developments in medical weight management have prompted Southwest Florida healthcare providers to report significant patient success rates with FDA-approved medications and comprehensive treatment protocols. Premier Wellness Florida, operating from its Del Prado Boulevard facility, has documented patient…
Winkler Kurtz LLP - Long Island Lawyers Port Jefferson Station Injury Attorney O …
Winkler Kurtz LLP is a leading Long Island law firm specializing in personal injury cases such as car accidents, slip and falls, and medical malpractice. Offering decades of local experience, the firm provides compassionate support and skilled legal advocacy to help injury victims secure justice and compensation. With free consultations and a contingency fee policy, Winkler Kurtz LLP ensures quality legal help is available to all Long Islanders in need.
When…
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
More Releases for Acral
Chemotherapy Induced Acral Erythema Treatment Market | Exploring Current Trends …
Chemotherapy Induced Acral Erythema Treatment Market size was valued at USD 1.5 Billion in 2024 and is forecasted to grow at a CAGR of 7.1% from 2026 to 2033, reaching USD 2.8 Billion by 2033.
Chemotherapy Induced Acral Erythema Treatment Market Outlook and Investment Analysis
What is the current outlook of the Chemotherapy Induced Acral Erythema Treatment Market?
The Chemotherapy Induced Acral Erythema (CAAE) Treatment Market is witnessing significant growth due to the…
Chemotherapy-Induced Acral Erythema Market Giants Spending Is Going to Boom
The Global Chemotherapy-Induced Acral Erythema Market Report by Absolute Markets Insights contains the market strategy, market orientation, expert opinion and knowledgeable information. It is an in-depth study analyzing the current state of the Chemotherapy-Induced Acral Erythema Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Chemotherapy-Induced Acral Erythema Market…
Acral Lentiginous Melanoma Market Size, Opportunity, Analysis & Trends 2023-2033
Acral Lentiginous Melanoma Market Report Overview:
Report Attribute Details
Base Year 2022
Forecast Years 2023-2033
Historical Years 2017-2022
Market Growth (2023-2033) 3.44%
The report offers a comprehensive analysis of the acral lentiginous melanoma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report…
2023: Acral Lentiginous Melanoma Drugs Market to reach US$ 90 million in 2029
The Acral Lentiginous Melanoma Drugs market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status…
The Next Decade See Chemotherapy-Induced Acral Erythema Market Pushed Towards Ex …
According to latest research by Persistence Market Research, Chemotherapy-Induced Acral Erythema Market is set to witness steady growth during 2021-2031.
Increase in usage of chemotherapeutic agents due to increasing prevalence of cancers is the major growth driver of chemotherapy induced acral erythema treatment market.
Acral erythema is also known as hand-foot syndrome or palmoplantar erythrodysesthesia. Acryl erythema is a result of adverse drug reaction typically occur after several months of treatment with…
Global Acral lentiginous melanoma - Market Report Forecast to 2027
A melanoma that develops on the palms of the hands, the soles of the feet, or under the nails is known as acral lentiginous melanoma (ALM). The name "acral" comes from the Greek word "extremity," and it alludes to the appearance of this form of melanoma on the extremities. The term "lentiginous" refers to how melanoma spots are frequently significantly darker than the surrounding skin. ALM is the most frequent…
